2026 Global: Cardiac Rhythm Management Devices-Competitive Review (2032) report
Description
The 2026 Global: Cardiac Rhythm Management Devices-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cardiac rhythm management devices by geography and historical trend. The scope of the report extends to sizing of the cardiac rhythm management devices market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Medtronic, Abbott, and Boston Scientific are widely recognized as the three dominant companies in cardiac rhythm management (CRM), each offering comprehensive portfolios spanning pacemakers, implantable cardioverter-defibrillators (ICDs), cardiac resynchronization therapy (CRT) devices and remote monitoring systems; Medtronic leads in global share and MRI‑conditional devices while Abbott and Boston Scientific compete strongly in CRT and miniaturized implantable monitors respectively. BIOTRONIK and MicroPort (including MicroPort CRM) are important challengers: BIOTRONIK is noted for long‑life batteries, home‑monitoring platforms and strong European presence, and MicroPort leverages cost‑competitive devices and growth in Asia-Pacific markets. Philips (including its BioTelemetry business) and GE HealthCare provide critical remote monitoring, telemetry and diagnostic ecosystems that integrate with CRM implants and hospital systems, supporting data analytics and cloud connectivity that improve long‑term rhythm management workflows.
LivaNova, Lepu Medical, and Asahi Kasei round out the set of major players with specialized strengths: LivaNova focuses on select implantable therapies and surgical cardiac devices and maintains presence in niche CRM segments, Lepu Medical has expanded rapidly in China with competitive pacemaker and monitor offerings, and Asahi Kasei participates through components, sensing technologies and partnerships that feed into CRM supply chains. Stryker and Nihon Kohden appear in many industry listings as additional influential firms—Stryker through acquisition‑led expansion into electrophysiology tools and procedural equipment, and Nihon Kohden through monitoring and diagnostic equipment—although their CRM implant market shares are smaller compared with the top-tier implant vendors. Several reports note that Medtronic, Boston Scientific and Abbott together account for the vast majority of global CRM revenue, with Biotronik and LivaNova as the next largest implant-focused competitors and a broader cohort (MicroPort, Philips, Lepu, Asahi Kasei, Stryker/Nihon Kohden) supplying complementary devices, monitoring platforms and regional alternatives.
Market dynamics emphasize miniaturization, leadless pacing, MRI compatibility, remote/home monitoring and the emergence of pulsed‑field ablation and AI‑enabled diagnostics as differentiators that vendors use to capture share; Medtronic’s Micra leadless pacemaker and strong MRI‑conditional line, Abbott’s multipoint left‑ventricular pacing and Bluetooth‑enabled monitors, and Boston Scientific’s electrophysiology mapping and emerging pulsed‑field technologies are emblematic of these trends. Regional growth is strongest in North America and Asia‑Pacific, driving vendors to invest in R&D, digital ecosystems and localized manufacturing to address aging populations and rising atrial fibrillation prevalence, while regulatory approvals and reimbursement remain key determinants of competitive positioning across the top CRM companies.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cardiac rhythm management devices by geography and historical trend. The scope of the report extends to sizing of the cardiac rhythm management devices market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Medtronic, Abbott, and Boston Scientific are widely recognized as the three dominant companies in cardiac rhythm management (CRM), each offering comprehensive portfolios spanning pacemakers, implantable cardioverter-defibrillators (ICDs), cardiac resynchronization therapy (CRT) devices and remote monitoring systems; Medtronic leads in global share and MRI‑conditional devices while Abbott and Boston Scientific compete strongly in CRT and miniaturized implantable monitors respectively. BIOTRONIK and MicroPort (including MicroPort CRM) are important challengers: BIOTRONIK is noted for long‑life batteries, home‑monitoring platforms and strong European presence, and MicroPort leverages cost‑competitive devices and growth in Asia-Pacific markets. Philips (including its BioTelemetry business) and GE HealthCare provide critical remote monitoring, telemetry and diagnostic ecosystems that integrate with CRM implants and hospital systems, supporting data analytics and cloud connectivity that improve long‑term rhythm management workflows.
LivaNova, Lepu Medical, and Asahi Kasei round out the set of major players with specialized strengths: LivaNova focuses on select implantable therapies and surgical cardiac devices and maintains presence in niche CRM segments, Lepu Medical has expanded rapidly in China with competitive pacemaker and monitor offerings, and Asahi Kasei participates through components, sensing technologies and partnerships that feed into CRM supply chains. Stryker and Nihon Kohden appear in many industry listings as additional influential firms—Stryker through acquisition‑led expansion into electrophysiology tools and procedural equipment, and Nihon Kohden through monitoring and diagnostic equipment—although their CRM implant market shares are smaller compared with the top-tier implant vendors. Several reports note that Medtronic, Boston Scientific and Abbott together account for the vast majority of global CRM revenue, with Biotronik and LivaNova as the next largest implant-focused competitors and a broader cohort (MicroPort, Philips, Lepu, Asahi Kasei, Stryker/Nihon Kohden) supplying complementary devices, monitoring platforms and regional alternatives.
Market dynamics emphasize miniaturization, leadless pacing, MRI compatibility, remote/home monitoring and the emergence of pulsed‑field ablation and AI‑enabled diagnostics as differentiators that vendors use to capture share; Medtronic’s Micra leadless pacemaker and strong MRI‑conditional line, Abbott’s multipoint left‑ventricular pacing and Bluetooth‑enabled monitors, and Boston Scientific’s electrophysiology mapping and emerging pulsed‑field technologies are emblematic of these trends. Regional growth is strongest in North America and Asia‑Pacific, driving vendors to invest in R&D, digital ecosystems and localized manufacturing to address aging populations and rising atrial fibrillation prevalence, while regulatory approvals and reimbursement remain key determinants of competitive positioning across the top CRM companies.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
